FHIR © HL7.org  |  Server Home  |  XIG Home  |  Server Source  |  FHIR  

FHIR IG Statistics: FHIR Resources

Resources - All Kinds, Realm US

18,267 resources

Type: Text:

By Version

By Authority

 

Start Prev Rows 6800 - 7000 Next

PackageVersionIdentityName/TitleStatusFMMWGDateAuth
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1096.95Recommendations Related to Medication Regimen, Change Medication Courseactive2017-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1096.97Recommendations Related to Medication Regimen, Change Medication Dosing Intervalactive2017-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1096.98Recommendations Related to Medication Regimen, Discontinue Medicationactive2017-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1096.99Recommendations Related to Medication Regimen, Monitoringactive2021-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1099.12Medication Routeactive2024-06hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1099.24Extended Pregnancy Statusactive2023-07hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1099.33External Cause of Injury/Morbidityactive2025-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1099.35Arthritis Feedback Types (SNOMED)active2019-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1099.36Arthritis Feedback Types (LOINC)active2025-05hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1099.45Bidirectional Services eReferral Typeactive2025-05hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1099.46Bidirectional Services eReferral Reasonactive2025-05hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1099.50Transport vehicle typeactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1099.54Specimen typeactive2024-06hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1099.55At Home In Vitro Patient Questionsactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1099.58Acute COVID 19 Diagnosisactive2023-07hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1102.1Case Management for Behavioral Healthactive2021-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1102.63Case Management for Behavioral Healthactive2021-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1102.64Case Management for Behavioral Healthactive2021-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1108.124Follow Up Within 6 Monthsactive2024-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1108.125Follow Up Within 6 Monthsactive2024-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1108.126Bone Scanactive2024-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1108.127Bone Scanactive2024-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1108.15Hospice Care Ambulatoryactive2024-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1108.175Office and Wellness Visits for General Screeningactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1108.176Office and Wellness Visits for General Screeningactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1108.177Office and Wellness Visits for General Screeningactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1108.178Office and Wellness Visits for General Screeningactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1108.28Non Acute Encounter Codes CPTactive2024-06hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1108.29Non Acute Encounter Codes HCPCSactive2024-06hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1108.31Bleeding Event Diagnosis Codes ICD9active2024-06hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1108.78Statin Associated Muscle Symptomsactive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1108.84Statin Associated Muscle Symptomsactive2024-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1108.85Statin Associated Muscle Symptomsactive2024-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1108.99Underweightactive2022-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1110.11Cornual Ectopic Pregnancyactive2021-06hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1110.12Cornual Ectopic Pregnancyactive2021-06hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1110.13Perforation of Uterusactive2021-06hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1110.14Perforation of Uterusactive2021-06hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1110.15Uterine Ruptureactive2021-06hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1110.16Uterine Ruptureactive2021-06hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1110.17Transabdominal Cerclageactive2021-06hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1110.18Transabdominal Cerclageactive2022-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1110.2Transabdominal Cerclageactive2021-06hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1110.21Intravenous or Intraarterial Thrombolytic tPA Therapy Prior to Arrivalactive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1110.23Intensive Care Unitactive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1110.24Uterine Hornactive2021-06hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1110.25Metroplastyactive2021-06hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1110.3Medical Induction of Laboractive2021-06hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1110.35Placenta Previaactive2021-06hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1110.36Placenta Accreta Spectrum Previa or Vasa Previaactive2024-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1110.37Placenta Accreta Spectrum Previa or Vasa Previaactive2023-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1110.38Outpatient Surgery Serviceactive2019-04hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1110.41Statin Allergenactive2022-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1110.42Statin Allergenactive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1110.50Rivaroxaban for VTE Prophylaxisactive2022-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1110.51Prasugrelactive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1110.52Pharmacological Contraindications For Antithrombotic Therapyactive2022-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1110.53Acute Renal Failureactive2024-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1110.54Total Parenteral Nutritionactive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1110.55Intravenous Thrombolytic tPA Therapyactive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1110.56Intraarterial Thrombolytic tPA Therapyactive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1110.57Ischemic Stroke Thrombosisactive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1110.58Ischemic Stroke Thrombosisactive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1110.59Ischemic Stroke Otheractive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1110.60Ischemic Stroke Otheractive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1110.61Antithrombotic Therapy Antiplateletactive2025-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1110.62Antithrombotic Therapy for Ischemic Strokeactive2021-04hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1110.63Present On Admission is Yes or Exemptactive2022-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1110.64Application of Venous Foot Pumpsactive2022-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1110.65Application of Intermittent Pneumatic Compression Devicesactive2022-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1110.66Application of Graduated Compression Stockingsactive2022-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1110.6720 to 42 Plus Weeks Gestationactive2023-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1110.6837 to 42 Plus Weeks Gestationactive2023-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1110.6937 to 38 Weeks Gestationactive2023-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1110.7020 to 42 Plus Weeks Gestationactive2023-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1110.7120 to 42 Plus Weeks Gestationactive2025-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1110.7237 to 42 Plus Weeks Gestationactive2023-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1110.7337 to 42 Plus Weeks Gestationactive2023-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1110.7437 to 38 Weeks Gestationactive2023-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1110.7537 to 38 Weeks Gestationactive2023-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1110.76History of Atrial Ablationactive2022-11hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1110.77Placenta Accreta Spectrum Previa or Vasa Previaactive2024-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1110.78Placenta Previaactive2023-11hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1111.143Observation Servicesactive2021-06hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1111.159All Primary and Secondary Canceractive2023-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1111.161All Primary and Secondary Canceractive2022-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1111.163Emergency Department Evaluationactive2020-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1111.164Admit Inpatientactive2021-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1111.171Opioid Use Disorderactive2024-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1111.173Sickle Cell Disease with and without Crisis SNOMEDactive2024-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1111.174Sickle Cell Disease with and without Crisis ICDactive2024-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1111.175Sickle Cell Disease with and without Crisisactive2024-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1111.176Opioid Medication Assisted Treatment (MAT) HCPCSactive2024-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1111.177Opioid Medication Assisted Treatment (MAT)active2025-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1111.178Cancer Related Pain ICD 10active2024-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1111.179Cancer Related Pain SNOMEDactive2024-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1111.180Cancer Related Painactive2024-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1115.10Care Experience Preferences at End of Life LOINCactive2024-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1115.12Healthcare Agent Ordinalityactive2020-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1115.14ADIClauseTypeVSactive2022-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1115.17Preconditions for Treatment Preferencesactive2024-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1115.22Advance Directive Document Typesactive2024-07hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1115.23AD Conditions and Prognosis Scenariosactive2023-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1115.26Healthcare Agent or Advisor Indicatoractive2024-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1115.27Initial Treatment portable medical order optionsactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1115.28Cardiopulmonary Resuscitation Order Optionsactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1115.30Cardiopulmonary Resuscitation Order Proceduresactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1115.31Cardiopulmonary Resuscitation Procedures Groupingactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1115.32Additional Portable Medical Order Proceduresactive2025-04hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1115.33Initial Treatment Portable Medical Order Procedures Groupingactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1115.34Additional portable medical order Procedures Groupingactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1115.35Medically Assisted Nutrition Order Optionsactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1115.36Medically Assisted Nutrition Portable Medical Order Procedures Groupingactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1115.37Healthcare Agent Powersactive2024-11hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1115.38Personal Health Goal Options LOINCactive2025-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1115.40Portable Medical Order Document Typesactive2025-04hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1115.41Advance Healthcare Directive Document Types Grouperactive2025-04hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1115.8Treatment Intervention Preferences at End of Life LOINCactive2025-04hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.1Rituximab Injectableactive2024-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.100Pathological M Stage M1cactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.101Pathological N Stage N3active2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.102N Stage pN1aactive2024-06hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.103N Stage pN1bactive2024-06hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.105Pathological N Stage pN1miactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.106Pathological N Stage N2bactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.107Pathological N Stage N2aactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.108Pathological N Stage N2active2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.109Pathological N Stage N1bactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.110Pathological N Stage N1aactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.112Pathological N Stage N0active2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.114Pathological T Stage T4dactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.115Pathological T Stage T4cactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.116Pathological T Stage T4bactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.117Pathological T Stage T4aactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.118Pathological T Stage T4active2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.120N Stage N2Cactive2024-06hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.121T Stage T3cactive2024-06hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.122T Stage T3bactive2024-06hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.123T Stage T3aactive2024-06hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.124Pathological T Stage T3active2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.125T Stage T2cactive2024-06hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.126T Stage T2bactive2024-06hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.127T Stage T2aactive2024-06hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.128Pathological T Stage T2active2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.129Pathological T Stage T1cactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.132Pathological T Stage T1bactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.135Pathological T Stage T1aactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.136Pathological T Stage T1active2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.137Pathological T Stage T1micactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.139Pathological T Stage T0active2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.142Cancer Stage IIIactive2024-07hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.143Cancer Stage IIIAactive2024-07hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.144Cancer Stage IIIBactive2024-07hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.145Cancer Stage IIICactive2024-07hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.146Cancer Stage IVactive2024-07hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.147Cancer Stage IVAactive2024-07hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.148Cancer Stage IVBactive2024-07hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.149Cancer Stage IVCactive2024-07hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.151Cisplatin Injectableactive2024-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.153Vinorelbine Injectableactive2024-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.154Gemcitabine Injectableactive2024-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.155Docetaxelactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.156Pemetrexed Injectableactive2024-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.158Vinblastine Injectableactive2024-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.160ECOG Performance Statusactive2024-07hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.161ECOG Performance Statusactive2020-10hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.162ECOG Performance Statusactive2022-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.164Karnofsky Performance Statusactive2024-07hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.165Carboplatin Injectableactive2020-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.166Paclitaxelactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.168Doxorubicin Injectableactive2022-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.169Irinotecan Injectableactive2024-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.179Bevacizumab Injectableactive2024-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.181Methotrexateactive2024-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.184Breast Canceractive2022-06hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.185Breast Canceractive2023-07hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.191Cancer Stage IIactive2024-07hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.192Cancer Stage IIAactive2024-07hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.193Cancer Stage IIBactive2024-07hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.194Pertuzumab Injectableactive2024-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.196Ixabepilone Injectableactive2024-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.197Goserelinactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.200Epirubicin Injectableactive2024-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.202Ramucirumab Injectableactive2024-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.204Letrozoleactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.206Exemestaneactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.209Fluorouracilactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.210Capecitabine Oralactive2024-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.222Aprepitant Oralactive2024-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.223Fosaprepitant Injectableactive2024-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.255Colorectal Canceractive2021-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.256Colorectal Canceractive2021-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.257Colorectal Cancer Chemotherapyactive2023-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.280Cancer Stage IAactive2024-07hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.281Cancer Stage IBactive2024-07hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.286Cancer Stage IICactive2024-07hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.291Positive Resultactive2024-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.292Negative Resultactive2015-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.300Pathological N Stage N1Cactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.332Daunorubicin Injectableactive2024-12hl7